stem cell-based assay
Celcuity, Puma Bio Collaborate on Clinical Trial
Celcuity's HER2 assay will be used to assess Puma Bio's Nerlynx and chemotherapy on patients with early-stage triple-negative breast cancer.
Amarantus Reacquires Neurology Diagnostic Assets from Avant
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
Emosis Gets CE Mark for Heparin-Induced Thrombocytopenia Test
The flow cytometry-based HIT Confirm test is a first-in-class functional test that provides results in 30 minutes, according to Emosis.
Celcuity Net Loss Spikes in Q3
In the third quarter, the firm inked a new lease agreement and completed its initial public offering, receiving aggregate net proceeds of $23.3 million.
Celcuity Raises $26.2M in IPO
The cell-based diagnostics firm sold a total of 2.76 million shares, including 360,000 shares to the offering's underwriter.